Alkermes plc, of Dublin, reported the start of a second phase II study of its broad-spectrum oral antipsychotic ALKS 3831 in development for schizophrenia. It will assess the compound's efficacy, safety and tolerability in treating schizophrenia in patients with co-occurring alcohol use disorder, compared to olanzapine, an approved antipsychotic medicine.